Prognostic biomarkers in resected colorectal cancer: implications for adjuvant chemotherapy.

Abstract:

:Knowledge of the prognostic role of biomarkers in colorectal cancer is limited and the routine determination for clinical practice is not warranted. However, for some of these markers, data are promising enough for further evaluation. This review addresses a comprehensive analysis of prognostic biomarkers in colorectal cancer. Data from published studies were collected and analyzed. A sufficient level of evidence suggests that DNA indexes, angiogenesis indicators and some genetic/biochemical markers identity prognostic differences in patients with early-stage colorectal cancer. High-risk patients could be the target for future adjuvant chemotherapy trials and one or more of these markers may identify prognostic subgroups with the same TNM stage category.

authors

Graziano F,Catalano V,Baldelli AM,Cascinu S

doi

10.1586/14737140.1.2.247

keywords:

subject

Has Abstract

pub_date

2001-08-01 00:00:00

pages

247-57

issue

2

eissn

1473-7140

issn

1744-8328

pii

ERA010210

journal_volume

1

pub_type

杂志文章,评审
  • miRNA as markers for the diagnostic screening of colon cancer.

    abstract::Early screening for colon cancer (CC) allows for early stage diagnosis of the malignancy and potentially reduces disease mortality as the cancer is most likely curable at its earliest stages. Early detection would be desirable if accurate, practical and cost-effective diagnostic measures for this cancer were available...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.869479

    authors: Ahmed FE

    更新日期:2014-04-01 00:00:00

  • Unresolved issues in diffuse large B-cell lymphomas.

    abstract::For more than 25 years, the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was considered the 'gold standard' for the treatment of aggressive lymphomas, 90% of which are diffuse large B-cell lymphomas (DLBCLs). After the demonstration of rituximab's single-agent activity in DLBCL, a pi...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.170

    authors: Murawski N,Zwick C,Pfreundschuh M

    更新日期:2010-03-01 00:00:00

  • Capecitabine in the treatment of colorectal cancer.

    abstract::Capecitabine is an oral prodrug of 5-fluorouracil. It is being increasingly used in the treatment of colorectal cancer in both the adjuvant and metastatic settings. This review aims to explore the data in relation to the pharmacology and mode of action of capecitabine, followed by an in-depth review of the available c...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.6.803

    authors: Kelly C,Cassidy J

    更新日期:2007-06-01 00:00:00

  • Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities.

    abstract:INTRODUCTION:Cancer genome sequencing studies have discovered mutations in members of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin-remodeling complex in nearly 25% of human cancers. The SWI/SNF complex, first discovered in S. cerevisiae, shows strong conservation from yeast to Drosophila to mammals, contains ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1605905

    authors: Orlando KA,Nguyen V,Raab JR,Walhart T,Weissman BE

    更新日期:2019-05-01 00:00:00

  • Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment.

    abstract::With the introduction of orally-active, potent and selective third-generation aromatase inhibitors and inactivators--anastrozole, letrozole and exemestane--approaches to the treatment of advanced breast cancer are undergoing re-evaluation. In advanced breast cancer, aromatase inhibitors and inactivators are likely to ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2.3.267

    authors: Dixon JM

    更新日期:2002-06-01 00:00:00

  • Nivolumab for the treatment of colorectal cancer.

    abstract:INTRODUCTION:Despite a variety of therapies for advanced metastatic colorectal cancer being available, the outcomes in this malignancy remain suboptimal. Immunotherapy has been slow to impact the management of this patient group. Checkpoint inhibitors, such as nivolumab, have had disappointing results when used broadly...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1480942

    authors: Smith KM,Desai J

    更新日期:2018-07-01 00:00:00

  • Current radiotherapy techniques in NSCLC: challenges and potential solutions.

    abstract::Introduction: Radiotherapy is an important therapeutic strategy in the management of non-small cell lung cancer (NSCLC). In recent decades, technological implementations and the introduction of image guided radiotherapy (IGRT) have significantly increased the accuracy and tolerability of radiation therapy.Area covered...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2020.1760094

    authors: Giaj-Levra N,Borghetti P,Bruni A,Ciammella P,Cuccia F,Fozza A,Franceschini D,Scotti V,Vagge S,Alongi F

    更新日期:2020-05-01 00:00:00

  • Screening for ovarian cancer.

    abstract::Ovarian cancer frequently presents late, when chances for long-term survival are poor. The increased survival advantage for patients diagnosed with early-stage ovarian cancer suggests that screening to detect early-stage disease might have an impact on disease mortality. Attempts are being made to develop effective sc...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.1.55

    authors: Lewis S,Menon U

    更新日期:2003-02-01 00:00:00

  • Clinical implications of lung neuroendocrine neoplasm classification.

    abstract:INTRODUCTION:Neuroendocrine neoplasms of the lung (Lung NENs) encompass NE tumors (NETs), which are in turn split into typical and atypical carcinoids, and NE carcinomas (NECs), which group together small-cell carcinoma and large-cell NE carcinoma. This classification is the current basis for orienting the daily practi...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1862654

    authors: Metovic J,Barella M,Harari S,Pattini L,Albini A,Sonzogni A,Veronesi G,Papotti M,Pelosi G

    更新日期:2020-12-24 00:00:00

  • Role of intensity-modulated radiation therapy in gastrointestinal cancer.

    abstract::Intensity-modulated radiation therapy (IMRT) represents a powerful advance in the planning and delivery of radiation therapy owing to its ability to deliver highly conformal treatment doses while sparing normal tissues. Dosimetric studies have shown the feasibility and theoretical benefit of treating with IMRT over 3D...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.16

    authors: Bockbrader M,Kim E

    更新日期:2009-05-01 00:00:00

  • Clinical outcome after cystectomy in patients with lymph node-positive bladder cancer.

    abstract::Whereas radical cystectomy is the standard of care in high-grade, invasive bladder tumors, the extent of lymphadenectomy and its diagnostic and/or therapeutic potential is controversial. Independent predictors for lymph node involvement are T-stage, histological grading and lymphovascular invasion. Preoperative assess...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.6.871

    authors: Nagele U,Anastasiadis AG,Merseburger AS,Sievert KD,Stenzl A,Kuczyk M

    更新日期:2006-06-01 00:00:00

  • Hepatocellular cancer in HIV-infected individuals: tomorrow's problem?

    abstract::A number of cancers occur with increased frequency in individuals with HIV infection. There is a debate as to whether or not hepatocellular cancer is one of these tumors. This article reviews the current data regarding incidence etiology, treatment and outcome for HIV-related hepatocellular cancer. It also attempts to...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.11.1553

    authors: Powles T,Macdonald D,Nelson M,Stebbing J

    更新日期:2006-11-01 00:00:00

  • Breast cancer chemoprevention.

    abstract::According to the National Cancer Institute Surveillance Epidemiology and End Results Cancer Statistics Review, the incidence of invasive breast cancer in the USA is 124 women per 100,000 population. Women at increased risk for breast cancer have three major options to reduce their risk, specifically screening, chemopr...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.206

    authors: Gabriel EM,Jatoi I

    更新日期:2012-02-01 00:00:00

  • Robotic-assisted radical prostatectomy in 2010.

    abstract::This article reviews the current status of robotic-assisted radical prostatectomy (RARP) with outcome analysis. The published English literature (PubMed) database was searched extensively for major publications and large series on RARP. The search was carried out over the preceding 3-year period. Selected series were ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.35

    authors: Singh I,Hemal AK

    更新日期:2010-05-01 00:00:00

  • Minimally invasive cystectomy approaches in the treatment of bladder cancer.

    abstract::Bladder cancer is the most frequently occurring tumor of the urinary system, with over 10,000 new diagnoses each year in the UK. Approximately 70% of these are non-muscle-invasive and limited to the mucosa (Ta) or submucosa (T1). These tumors are generally managed with transurethral resection followed by adjuvant intr...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.52

    authors: Cheung G,Dasgupta P,Guru KA,Billia M,Khan MS

    更新日期:2012-06-01 00:00:00

  • Proteasome inhibitors in the treatment of multiple myeloma.

    abstract::Proteasome inhibition has been shown to be an effective strategy for the treatment of multiple myeloma, as demonstrated by the clinical activity of the first-in-class agent bortezomib. Recently, the second-generation proteasome inhibitor carfilzomib has been approved in the USA in the relapsed and refractory setting, ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.13.9

    authors: McBride A,Ryan PY

    更新日期:2013-03-01 00:00:00

  • What therapies are on the horizon for HER2 positive breast cancer?

    abstract::Introduction: Despite dramatic improvements in survival achieved with currently available anti-HER2 agents, HER2-positive metastatic breast cancer remains an almost invariably deadly disease, with primary or acquired resistance to HER2-directed agents developing during treatment. Many efforts are focused on identifyin...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1660164

    authors: Viale G,Morganti S,Ferraro E,Zagami P,Marra A,Curigliano G

    更新日期:2019-09-01 00:00:00

  • Advances in radiation therapy of head and neck cancer.

    abstract::Head and neck cancer is the fifth most common cancer in the USA. Although there have been major improvements in surgical and radiation techniques, the overall survival has not changed significantly in the last decade. The major changes occurring in recent years have been in the ability to preserve organs and to improv...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.4.633

    authors: Popovtzer A,Eisbruch A

    更新日期:2008-04-01 00:00:00

  • Advances in diagnosis and management of oligodendroglioma.

    abstract::Oligodendrogliomas are primary brain tumors, genetically characterized by chromosomal alterations in the 1p and 19q. Recent clinical trials have shown that oligodendrogliomas are sensitive to PCV chemotherapy with 60-65% of patients responding and median response duration of 1-1.5 years. The response rate in mixed oli...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2.5.520

    authors: Hussein MR,Baidas S

    更新日期:2002-10-01 00:00:00

  • Adrenocortical carcinoma: role of laparoscopic surgery in treatment.

    abstract::Adrenocortical carcinoma is a rare disorder with a prevalence of one case per 1.7 million people and a generally poor prognosis. It accounts for 0.02% of all cancer cases and 0.2% of cancer deaths. Within the past three decades, accurate diagnosis, precise radiologic localization, satisfactory preoperative medical man...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.9.1295

    authors: Haleblian GE,Wilson C,Haddad D,Albala DM

    更新日期:2007-09-01 00:00:00

  • Combining surgery and chemotherapy for invasive bladder cancer: current and future directions.

    abstract::More than 13,000 patients died from invasive bladder cancer in 2005 alone. Radical cystectomy is the most commonly prescribed treatment for patients with muscle-invasive bladder cancer, or for those with a nonmuscle-invasive disease that is refractory to intravesical therapy. Despite advances in surgical technique and...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.2.281

    authors: Amiel GE,Lerner SP

    更新日期:2006-02-01 00:00:00

  • Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects.

    abstract::Several nanoformulated anti-cancer substances are currently commercialized or under development. Pre-clinical and clinical results have revealed better properties, that is, larger efficacy and lower toxicity for these substances than for conventional anti-cancer treatments. Here, we review the development of several o...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2015.1086647

    authors: Alphandéry E,Grand-Dewyse P,Lefèvre R,Mandawala C,Durand-Dubief M

    更新日期:2015-01-01 00:00:00

  • Current surgical treatment of intermediate risk differentiated thyroid cancer: a systematic review.

    abstract::Introduction: Surgical treatment of thyroid cancer has become less aggressive but for many patients, the threshold for performing total thyroidectomy (TT), as opposed to thyroid lobectomy (TL), has remained unclear. Current American Thyroid Association (ATA) guidelines encourage more individualization of treatment opt...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1850280

    authors: Guo MY,Wiseman JJ,Wiseman SM

    更新日期:2020-12-15 00:00:00

  • Role and value of diffusion-weighted MRI in the radiotherapeutic management of head and neck cancer.

    abstract::With the association of concurrent chemotherapy, the widespread implementation of altered fractionation schedules and the use of more conformal radiotherapy techniques, the locoregional management of patients with squamous cell carcinoma of the head and neck region (HNSCC) has greatly improved over the last decades. H...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.121

    authors: Lambrecht M,Dirix P,Vandecaveye V,De Keyzer F,Hermans R,Nuyts S

    更新日期:2010-09-01 00:00:00

  • Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals.

    abstract::Anemia is a frequent problem in cancer patients, especially in those treated with chemotherapy, and has an important negative impact on quality of life. Red blood cell transfusions provide clear but rather temporary comfort. The development of erythropoietic stimulating agents (ESAs) led to a more durable anemia treat...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.10.1347

    authors: Vansteenkiste J,Wauters I

    更新日期:2007-10-01 00:00:00

  • From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy.

    abstract::One of the most prominent pathways explored in the area of targeted therapy is the PI3K/Akt/mTOR pathway, which plays a central role in cell survival and proliferation. Deregulation of this pathway has been implicated in the promotion of cancer cell growth and survival. Inhibition of several steps of this pathway has ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.1.131

    authors: Georgakis GV,Younes A

    更新日期:2006-01-01 00:00:00

  • Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications.

    abstract::Advanced gastric cancer (GC) is a dreadful disease with a poor prognosis and the majority of patients die within 1 year of diagnosis. In the past decade, important signaling pathways promoting tumor proliferation and aggressiveness have been evaluated; the hepatocyte growth factor/mesenchymal epithelial transition (ME...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.974564

    authors: Abdel-Rahman O

    更新日期:2015-02-01 00:00:00

  • Raltitrexed in mesothelioma.

    abstract::Raltitrexed is a cytotoxic agent, rationally designed to inhibit a specific molecular target, thymidylate synthase. In contrast to other agents, raltitrexed inhibits thymidylate synthase directly and specifically in a mixed, noncompetitive manner, which may lead to an improved toxicity profile. After promising Phase I...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.136

    authors: Surmont VF,van Meerbeeck JP

    更新日期:2011-10-01 00:00:00

  • Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma.

    abstract::According to computed tomography image analysis, skeletal muscle (SM) and adipose tissue areas vary widely in patients with the same body mass index or the same body surface area. Body composition variables such as SM mass, SM density and subcutaneous and visceral adipose tissue have shown value as potential independe...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.866040

    authors: Antoun S,Lanoy E,Albiges-Sauvin L,Escudier B

    更新日期:2014-03-01 00:00:00

  • Treatment options for advanced pancreatic cancer: a review.

    abstract::Advanced pancreatic adenocarcinoma historically has a poor prognosis and the mortality rate has remained unchanged for over a decade. Common treatment options for patients with advanced pancreatic cancer include chemoradiation and/or chemotherapy. Single-agent gemcitabine has been considered the standard of care since...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.115

    authors: Warsame R,Grothey A

    更新日期:2012-10-01 00:00:00